Risk of hypospadias in offspring of women using loratadine during pregnancy: A systematic review and meta-analysis

Drug Safety

Volumn 31, Issue 9, 2008, Pages 775-788

  Schwarz, Eleanor B ^a   Moretti, Myla E ^b   Nayak, Smita ^a   Koren, Gideon ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Congenital disorders, drug induced; Histamine H1 receptor antagonists, adverse reactions; Hypospadias, drug induced; Loratadine, adverse reactions; Meta analysis; Pregnancy

Indexed keywords

ANTIHISTAMINIC AGENT; CLARITIN D; CYPROHEPTADINE; DESLORATADINE; LORATADINE;

ALLERGY; ARTICLE; BIBLIOGRAPHIC DATABASE; BRAZIL; CANADA; CASE CONTROL STUDY; COHORT ANALYSIS; CORRELATION ANALYSIS; DATA ANALYSIS; DENMARK; DROWSINESS; DRUG SAFETY; DRUG UTILIZATION; FETUS MALFORMATION; HIGH RISK POPULATION; HUMAN; HYPOSPADIAS; INCIDENCE; INFANT; ISRAEL; ITALY; MAJOR CLINICAL STUDY; MALE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL MODEL; SWEDEN; UNITED KINGDOM; UNITED STATES;

ABNORMALITIES, DRUG-INDUCED; ANTI-ALLERGIC AGENTS; FEMALE; HUMANS; HYPOSPADIAS; LORATADINE; MALE; MODELS, STATISTICAL; PREGNANCY; RISK;

EID: 49749088947     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831090-00006     Document Type: Article

References (26)

1. Mazzotta P, Loebstein R, Koren G. Treating allergic rhinitis in pregnancy: safety considerations. Drug Saf 1999; 20 (4): 361-75
2. Werler MM, Mitchell AA, Hernandez-Diaz S, et al. Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol 2005; 193 (3 Pt 1): 771-7
3. Glover DD, Amonkar M, Rybeck BF, et al. Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J Obstet Gynecol 2003; 188 (4): 1039-45
4. Gilbert C, Mazzotta P, Loebstein R, et al. Fetal safety of drugs used in the treatment of allergic rhinitis: a critical review. Drug Saf 2005; 28 (8): 707-19
5. Kallen B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Matern Fetal Neonatal Med 2002; 11 (3): 146-52
6. Kallen B, Olausson PO. Monitoring of maternal drug use and infant congenital malformations: does loratadine cause hypospadias? Int J Risk Safety Med 2001; 14: 115-9
7. Gallentine ML, Morey AF, Thompson Jr IM. Hypospadias: a contemporary epidemiologic assessment. Urology 2001; 57 (4): 788-90
8. Aberg A, Westbom L, Kallen B. Congenital malformations among infants whose mothers had gestational diabetes or preexisting diabetes. Early Hum Dev 2001; 61 (2): 85-95
9. Fredell L, Kockum I, Hansson E, et al. Heredity of hypospadias and the significance of low birth weight. J Urol 2002; 167 (3): 1423-7
10. Wennerholm UB, Bergh C, Hamberger L, et al. Incidence of congenital malformations in children born after ICSI. Hum Reprod 2000; 15 (4): 944-8
11. McIntyre BS, Vancutsem PM, Treinen KA, et al. Effects of perinatal loratadine exposure on male rat reproductive organ development. Reprod Toxicol 2003; 17 (6): 691-7
12. Willingham E, Agras K, Vilela M, et al. Loratadine exerts estrogen-like effects and disrupts penile development in the mouse. J Urol 2006; 175 (2): 723-6
13. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283 (15): 2008-12
14. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. 2006 [cited 2006 Nov 14]. OHRI [online]. Available from URL: http://www.ohri.ca/programs/ clini- cal_epidemiology/nosgen.doc [Accessed 2006 Nov 14]
15. Werler M, McCloskey C, Edmonds L, et al. Evaluation of an association between loratadine and hypospadias: United States, 1997-2001. Arch Dermatol 2004; 140 (7): 893-4
16. Pedersen L, Norgaard M, Skriver MV, et al. Prenatal exposure to loratadine in children with hypospadias: a nested case-control study within the Danish National Birth Cohort. Am J Ther 2006; 13 (4): 320-4
17. Pedersen L, Skriver MV, Norgaard M, et al. Maternal use of loratadine during pregnancy and risk of hypospadias in offspring. Int J Med Sci 2006; 3 (1): 21-5
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7 (3): 177-88
19. Brown JE, Stern H, Leeds T. Loratadine and pregnancy: outcomes in 49 pregnancies. Allergy Asthma Proc 1999; 20 (3): 199-200
20. Werler M, McCloskey C, Edmonds L, et al. Evaluation of an association between loratadine and hypospadias: United States, 1997-2001. JAMA 2004; 291 (15): 1828-30
21. Werler M, McCloskey C, Edmonds L, et al. Evaluation of an association between loratadine and hypospadias: United States, 1997-2001. MMWR Morb Mortal Wkly Rep 2004; 53 (10): 219-21
22. Diav-Citrin O, Shechtman S, Aharonovich A, et al. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol 2003; 111 (6): 1239-43
23. Kallen B, Olausson PO. No increased risk of infant hypospadias after maternal use of loratadine in early pregnancy. Int J Med Sci 2006; 3 (3): 106-7
24. Moretti ME, Caprara D, Coutinho CJ, et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin Immunol 2003; 111 (3): 479-83
25. Wilton LV, Pearce GL, Martin RM, et al. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998; 105 (8): 882-9
26. Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. Am J Perinatol 1997; 14 (3): 119-24